Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic editing to siRNA obesity therapies
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic…
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration…
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration…
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS platform
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS…
Lucid Diligence Brief: Lilly and NVIDIA AI Supercomputer partnership
Lucid Diligence Brief: Lilly and NVIDIA AI Supercomputer partnership…
Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design collaboration
Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design…
Artificial Intelligence and Digital Health Weekly News - August 18th 2025
AI in Healthcare Update: China’s AI Drug Discovery, GPT-five Medical Reasoning,…
Artificial Intelligence and Digital Health Weekly News - August 12th 2025
AI in Healthcare Update: GPT-five Launch, NASA Medical AI, Wearable…
Coupling state-of-the-art technologies: CRISPR in the service of CAR-T immunotherapy
Cancer is the second leading cause of death worldwide. Many research and…
Can Predictive Analytics redefine how we conduct Clinical Trials?
Clinical trials are essential for developing new treatments, discovering new…
Replication/ reproducibility crisis in preclinical studies. Is the end "in sight"?
Scientific development relies on knowledge/research credibility and validity.…